Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib in Relapsed/Refractory CLL or SLL
NCT00398112Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Aug 2007
- Primary completion
- Nov 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sunitinib in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), sponsored by National Cancer Institute. Started Aug 2007; status: completed.
02
Drugs
sunitinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT00398112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00398112.